Sun Allergy Treatment: A Stepwise Approach
- Solar urticaria is a rare but debilitating skin condition characterized by hives triggered by exposure to sunlight.Affecting an estimated 0.4% of all urticaria cases, and increasingly observed in...
- A thorough systematic review and meta-analysis published in the Journal of Clinical Medicine outlines a stepwise treatment strategy.
- For severe cases that don't respond to initial treatments, several options exist, though evidence is often based on smaller studies. Intravenous immunoglobulin (IVIG) has shown partial responses in...
Table of Contents
published August 22, 2025
Understanding Solar Urticaria
Solar urticaria is a rare but debilitating skin condition characterized by hives triggered by exposure to sunlight.Affecting an estimated 0.4% of all urticaria cases, and increasingly observed in children according to recent research, this condition can significantly diminish quality of life and restrict daily activities. Symptoms are provoked by specific wavelengths of light,primarily ultraviolet A (UVA) and visible light,as persistent through phototesting.
A Structured Treatment Approach
A thorough systematic review and meta-analysis published in the Journal of Clinical Medicine outlines a stepwise treatment strategy. the initial step involves high-dose H1 antihistamines, perhaps combined with leukotriene receptor antagonists. If these prove insufficient, phototherapy and immunotherapy with a biologic are considered subsequent options.
Treatment Options & Response Rates
| Treatment | Patients Studied | Overall Response Rate (95% CI) | Complete Response Rate (95% CI) |
|---|---|---|---|
| Antihistamines | 376 | 83% (70.4%-91.1%) | 7.7% (1.7%-28.3%) |
| UVB Phototherapy | 145 | 89.8% (77.9%-95.3%) | 39.8% (18.3%-66.1%) |
| Omalizumab (Xolair) | 76 | 93.2% (73.8%-98.5%) | 68.4% (48.5%-83.2%) |
Advanced Therapies for refractory Cases
For severe cases that don’t respond to initial treatments, several options exist, though evidence is often based on smaller studies. Intravenous immunoglobulin (IVIG) has shown partial responses in some patients, often in conjunction with phototherapy or antihistamines. Though, cyclosporine, while offering rapid relief, carries a risk of adverse effects and is generally not recommended for long-term use (beyond six months, per European guidance).
Plasmapheresis, an older treatment, has limited supporting evidence, with varying results observed in a small case series.
Expert Insight & Emerging Approaches
Adam Friedman, MD, FAAD, chair of Dermatology at The George Washington University, notes that when second-generation antihistamines fail to provide relief, hydroxychloroquine is often his preferred next step.This highlights the importance of individualized treatment plans tailored to the patient’s response.